Status:
WITHDRAWN
Detection of G-quadruplex DNA Methylation in Cancer
Lead Sponsor:
Zhongnan Hospital
Conditions:
Cancer
DNA G-quadruplex
Eligibility:
All Genders
42+ years
Brief Summary
This study aims to evaluate the early diagnosis value of G-quadruplex DNA methylation in patients with cancer.
Detailed Description
Global DNA hypomethylation is a hallmark of most cancers that occurs early during oncogenesis. We would like to investigate whether cancer-specific transcription factor binding to DNA G-quadruplex dri...
Eligibility Criteria
Inclusion
- Healthy volunteers identified as asymptomatic during medical examination;
- Age≥42 years old;
- Voluntarily participate in this study and sign the informed consent.
Exclusion
- History of malignancy or having achieved complete remission following tumor surgery;
- Certain autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis, Crohn's disease, IgA nephropathy, myasthenia gravis, dermatomyositis, immune thrombocytopenic purpura, etc.);
- Pregnancy;
- Acute trauma (including surgical procedures), sudden onset organ failure (e.g., resulting from a car accident, fulminant hepatic failure, acute pancreatitis, severe pneumonia due to influenza virus), or diagnosis of sepsis;
- Previous receipt of allogeneic blood transfusion, transplant surgery, or allogeneic cell therapy;
- Volunteers who cannot provide informed consent.
Key Trial Info
Start Date :
April 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06537063
Start Date
April 30 2024
End Date
December 30 2024
Last Update
January 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hubei Locations
Wuhan, Hubei, China, 430071